NEW YORK, Dec. 19, 2016 -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of Impax Laboratories, Inc. securities (NASDAQ:IPXL) from February 25, 2014 through November 3, 2016, both dates inclusive (the “Class Period”) of the important January 9, 2017 lead plaintiff deadline in the class action filed by the firm. The lawsuit seeks to recover damages for Impax investors under the federal securities laws.
To join the Impax class action, go to http://www.rosenlegal.com/cases-981.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, Defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Impax was engaging and/or had engaged in conduct that would cause the antitrust division of the U.S. Department of Justice (“DOJ”) and the Connecticut Attorney General to conduct extensive investigations of possible collusion of generic drug pricing; (2) the DOJ investigation and the underlying conduct was likely to result in criminal charges against Impax, and possibly its officers and directors, for collusion of generic drug pricing; (3) Impax lacked effective internal controls over financial reporting; and (4) as a result, Defendants’ public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 9, 2017. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-981.html or to discuss your rights or interests regarding this class action, please contact, Phillip Kim, Esq. or Kevin Chan, Esq. of The Rosen Law Firm toll free at 866-767-3653 or via email at [email protected] or [email protected]. Attorney Advertising. Prior results do not guarantee a similar outcome.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
Kevin Chan, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 34th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
[email protected]
[email protected]
www.rosenlegal.com


CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026
BlackRock CEO Larry Fink Earns $37.7 Million in 2025 Amid Record Growth
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations
TSMC Japan's Second Fab to Produce 3nm Chips by 2028
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure
Luxury Car Sales in the Middle East Take a Hit Amid Iran War
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate
Apple Turns 50: From Garage Startup to AI Crossroads
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 



